MCB-22-174
Selleck Chemicals
SKU:E4756-1MG
Couldn't load pickup availability

MCB-22-174 is annotated as an agonist in this dataset and is relevant to stem cell biology models. It is especially relevant when investigators need a named chemical input and interpretable readouts connected to compound-linked biochemical, transcriptional, and phenotypic responses in stem cell biology models.
Because the current annotation identifies MCB-22-174 as an agonist, it is suited to comparative profiling, concentration-response work, and follow-up studies that track compound-dependent signaling or phenotype changes without assuming a single assigned primary target. That positioning is consistent with agonist-response and downstream signaling studies and with follow-up studies that compare concentration-dependent responses across orthogonal assay formats. In stem cell biology models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.
Research Applications
- Agonist-response and downstream signaling studies
- Phenotypic profiling in stem cell biology models
- Combination studies with orthogonal perturbagens
- Mechanism-oriented follow-up using biochemical and cellular endpoints
Overall, MCB-22-174 is appropriate for mechanism-oriented studies that require an agonist-annotated compound for comparative profiling in stem cell biology models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.
- Research Area:
- Stem Cell Biology
- CAS No.:
- 3058199-58-6
- Molecular Weight:
- 429.37
- Formula:
- C₁₆H₁₄Cl₂DN₅OS₂
- Storage Temperature:
- -20°C
For Research Use Only. Not intended for diagnostic or therapeutic use.
Products may be subject to intellectual property rights.
The purchase of this product does not grant any license for commercial use, manufacturing, or clinical applications. The user is responsible for ensuring compliance with applicable laws and third-party rights.